Great Bay Bio Invites You to BPI US West 2025: Showcasing Site-Specific Integration for Accelerated Cell Line Development

The Global Biopharmaceutical Industry's Premier Event, BPI US West 2025, will be held from March 18-21 at the San Diego Convention Center in California, USA. It aims to shorten the cycle from lab to clinic by providing cutting-edge biomanufacturing technologies for mAbs, vaccines, and advanced therapies.This conference brings together over 1,000 scientists, executives, and technical leaders worldwide engaged in biopharmaceutical development and production, more than 90 exhibitors committed to accelerating product commercialization, and over 125 scientific case studies and new data presentations spanning five key areas.

▲BPI US West 2025

Dr. Liang Chen, Co-founder and CEO of Great Bay Bio, was invited to attend the conference., will attend this grand event with a booth (#321) as a team.And delivered a speech at the sub-forum Cell Line Development & Engineering on March 20th local time from 10:00-10:30 am, titled "Site-specific Integration Cell Line Development Application: From Target/Antibody Drug Discovery to Early CMC within 8 Months",Showcases GBB's innovative advantages in developing cell lines using cutting-edge technologies such as targeted integration, completing the vast workload from target/antibody drug discovery to early CMC within just 8 months.

▲GBB Co-Founder and CEO Dr. Liang Chen to Deliver Speech

BPI US West 2025 is a premier global event for biopharmaceuticals, aimed at shortening the time from lab to clinic by providing cutting-edge biomanufacturing technologies for mAbs, vaccines, and advanced therapies. This conference brings together industry leaders to share groundbreaking insights and the latest innovations, exploring with experts how artificial intelligence, sustainable practices, and advanced manufacturing are driving the industry forward, enhancing efficiency, precision, and quality across all stages of bioprocessing.